CELG News and Press, Celgene Corporation From 05/10/19

NEW YORK , May 10, 2019 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry to support user-driven innovation, and Celgene Corporation (NASDAQ: CELG) announced the 10 finalists chosen for the Lyfebulb-Celgene 2019 "Address...

Agios Pharmaceuticals ( AGIO ) announced FDA approval for its supplemental new drug application (sNDA) for TIBSOVO to treat newly diagnosed adult acute myeloid leukemia ((AML)) patients who have the IDH1 mutation and are ineligible for intensive chemotherapy. This newly expanded label wi...

Bristol-Myers Squibb (NYSE: BMY ) has priced a $19B offering of senior unsecured notes that will help fund its acquisition of Celgene (NASDAQ: CELG ). The debt will be offering in nine tranches. More news on: Bristol-Myers Squibb Company, Celgene Corporation, Healthcare stocks news, ...

Patients across all age subgroups treated with ozanimod lost less cortical grey matter volume than did those treated with interferon beta-1a over 24 months Data from new analysis of pivotal ozanimod trial will be presented at 2019 AAN Annual Meeting Celgene Corporation (NASDAQ:CE...

Targeting a market that could reach $1.1 trillion by 2050, Cortexyme ( CRTX ) will probably interest institutional investors. Besides, the company appears to have sufficient equity financing to complete its Phase 2-3 clinical trial. In addition, the fact that Pfizer ( PFE ) is among the shareh...

Market Assessment Bristol-Myers Squibb ( BMY ), a large cap ($79B) commercial stage biopharma, started the new year with a belated Christmas gift to shareholders. It announced the acquisition of Celgene ( CELG ) for $50/share in cash plus one BMY common share for each CELG share, valued ...

Merger activity decreased last week, with one new deal announced and three pending deals closing. Deal Statistics: New Deals: The acquisition of MidSouth Bancorp (MSL) by Hancock Whitney Corporation (HWC) for $101.79 million in an all-stock deal. Under the terms of the agreement,...

Introduction Those who read my previous articles, including my investment strategy statement , should be familiar with the investment approach that I have been sticking to - buying wonderful businesses at sensible prices. The core here is to evaluate the "wonderfulness," which points to fun...

Quick Take IDEAYA Biosciences ( IDYA ) has filed to raise gross proceeds of $70 million from a U.S. IPO, according to an S-1 registration statement . The firm is focused on the discovery and development of cancer therapeutics. IDYA is in Phase 1/2 trials (run by Novartis) for its lead c...

After Geron's ( GERN ) stock price experienced a meteoric rise and equally spectacular fall in the second half of 2018, it appears as though the stock might finally be about to stabilize. After reaching an intra-day high of $6.99 (market cap of $1.29B) on 09/13/18, Johnson & Johnson-owned ...